ClinicalTrials.gg
RecruitingNCT03720613Updated Sep 30, 2026

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

An observational study in Opioid-induced Constipation, sponsored by BioDelivery Sciences International. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by BioDelivery Sciences International · Observational

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 10 months later.
Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34,532
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Opioid-Induced Constipation with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Opioid-Induced Constipation · United States.

Started
2019
the only one that year
Observational
3 of 43
1 open now
Registered
43rd of 43
by date
Lead sponsor
1 of 43
BioDelivery Sciences International

Among the 43 studies in Opioid-Induced Constipation with a site in United States, this one is the only one that started in 2019, is one of 3 observational ones, and was the 43rd registered.

Opioid-Induced Constipation

87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.

Browse Opioid-Induced Constipation studies →

Open to participants now

1 of the 43 studies in Opioid-Induced Constipation with a site in United States is open now.

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Opioid-Induced Constipation studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Opioid-Induced Constipation with a site in United States, or all of them as a file.
02

Study summary

The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.

Read the detailed description

This is a prevalent new user cohort study conducted using multiple databases linkable to medical records and the National Death Index (NDI) to assess MACE risk among adult patients with chronic non-cancer pain receiving naldemedine or a comparator OIC medication. The uptake of naldemedine and comparator OIC medications will be monitored for each database annually until a sufficient number of patients to support the comparative analyses in the safety assessment phase is accrued. The safety assessment phase will commence at the conclusion of the monitoring phase.

03

Conditions studied

  • Opioid-induced Constipation

Keywords

  • naloxegol
  • major adverse cardiovascular event (MACE)
  • opioid induced constipation (OIC)
  • lubiprostone
  • naldemedine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will include new users of naldemedine or one of the comparator OIC medications (lubiprostone or naloxegol) who satisfy all of the inclusion criteria and none of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use in the database of either medication (index date)
  • At least two dispensings of opioids within six months prior to and including the index date, with at least a combined 31 cumulative days supply
  • At least 18 years of age or older on the index date
  • At least six months of continuous health plan coverage that includes medical and pharmacy benefits prior to and including the index date

Exclusion criteria

Exclusion Criteria:

  • Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the index date
  • Any cancer treatment or cancer pain diagnosis within six months before or on the index date
  • Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on the index date
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34,532 participants (estimated)
Patient registry
No

Groups and cohorts

  • Naldemedine

    Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.

    Drug: Naldemedine

  • Lubiprostone

    Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.

    Drug: Lubiprostone

  • Naloxegol

    Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.

    Drug: Naloxegol

Interventions

  • 0.2 mg tablet once a day at any time with or without food

    Also known as: Symproic®

  • 0.024 mg twice a day \[adjust dose based on liver function\]

    Also known as: Amitiza®

  • 25 mg tablet once a day in morning, 1 hour before or 2 hours after food

    Also known as: Movantik®

06

What researchers measure

Primary outcomes

  1. Number of Participants with a Major Adverse Cardiovascular Event

    A composite of major adverse cardiovascular events, cardiovascular (CV) death, nonfatal myocardial infarction (MI), and non-fatal stroke; participants with major adverse cardiovascular events will be identified using claims data and the national death index.

    Time frame: 5 years

Secondary outcomes

  1. Number of Participants with Cardiovascular Death

    Cardiovascular death is defined by the underlying cause of death and will include death from acute MI, sudden cardiac death, heart failure, stroke, cardiovascular procedure, cardiovascular hemorrhage, and other cardiovascular causes. Cardiovascular death will be identified using claims data and the national death index.

    Time frame: 5 years

  2. Number of Participants with Nonfatal Myocardial Infarction

    Participants with nonfatal myocardial infarction will be identified using claims data.

    Time frame: 5 years

  3. Number of Participants with Nonfatal Stroke

    Participants with nonfatal stroke will be identified using claims data.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Research Site
    Wilmington, Delaware 19801, United States
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2019 (actual). Primary completion is estimated for Jun 2029, 125 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2030 → Jun 2029 and completion Nov 2030 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Oct 25, 2018
StartActual
Jan 4, 2019
Primary completionEst.
Jun 30, 2029was Nov 2030
CompletionEst.
Jun 30, 2029was Nov 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2030→Jun 30, 2029
Sep 30, 2026
Study completion
Nov 1, 2030→Jun 30, 2029
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Nov 1, 2030→Jun 30, 2029
    Study completion Nov 1, 2030→Jun 30, 2029
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03720613
Lead sponsor
BioDelivery Sciences International
Collaborators
HealthCore, Inc.
Responsible party
Sponsor
First posted
Oct 25, 2018
Start date
Jan 4, 2019
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Todd Kunkel
Contact
tkunkel@bdsi.com
913-940-1789
Tom Smith
Contact
tsmith@bdsi.com
Stephen Lanes
principal investigator · HealthCore, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion